Adial Stockholders Approve 5x Authorized Share Increase and New Equity Plans

summarizeSummary

Adial stockholders approved a 5x increase in authorized shares and new equity compensation plans at the September 17 annual meeting, while the reverse merger vote was adjourned to October 1 pending Nasdaq approval.

check_boxKey Events · Corporate Governance and Compliance · ADIL

• Authorized Shares Increased 5x

  Stockholders approved increasing authorized common stock from 100,000,000 to 500,000,000 shares, providing headroom for the Azora reverse merger and PIPE financing.

• New Equity Plans Approved

  The 2026 Equity Incentive Plan reserves 3,078,147 shares plus annual 5% increases, and the 2026 ESPP reserves 307,815 shares plus annual 1% increases.

• Series F Warrant Issuance Approved

  Stockholders approved issuance of up to 552,940 shares upon exercise of Series F warrants from the November 2025 private placement.

• Reverse Merger Vote Adjourned

  Proposals 3-6, including the Azora reverse merger, were adjourned to October 1, 2026 at 8:30 a.m. ET pending Nasdaq conditional approval of the Initial Listing Application.

auto_awesomeAnalysis · ADIL · Life Sciences

Adial's stockholders approved increasing authorized shares from 100 million to 500 million, clearing the way for the massive dilution already quantified in the Azora reverse merger proxy. The vote also greenlit a new 2026 equity incentive plan with a 3.08 million share reserve and an employee stock purchase plan with 307,815 shares. Four remaining proposals — including the reverse merger itself — were adjourned to October 1 pending Nasdaq approval, keeping the company's survival financing in limbo.